June 15, 2024

Oral Contraceptive Pills Market Size to Surpass USD 92.80 Bn by 2033

The global oral contraceptive pills market size surpassed USD 23.71 billion in 2023 and is projected to be worth around USD 92.80 billion by 2033, expanding at a CAGR of 14.62% from 2024 to 2033.

Key Points

  • North America dominated the oral contraceptive pills market in 2023.
  • Asia Pacific is observed to witness the fastest rate of growth during the forecast period.
  • By type, the progestin only segment held a significant share of the market in 2023.
  • By category, the branded segment dominated the oral contraceptive pills market.
  • By distribution channel, the retail pharmacy segment dominated the market in 2023.

Oral Contraceptive Pills Market Size 2024 to 2033

The global oral contraceptive pills market is experiencing significant growth driven by factors such as increasing awareness about family planning, rising prevalence of unwanted pregnancies, and advancements in contraceptive technology. Oral contraceptive pills, commonly known as birth control pills, are a widely used form of contraception among women of reproductive age. They offer a convenient and reversible method of preventing pregnancy by inhibiting ovulation or altering the cervical mucus to prevent sperm from reaching the egg.

Get a Sample: https://www.precedenceresearch.com/sample/4159

Growth Factors:

Several factors contribute to the growth of the oral contraceptive pills market. Changing lifestyles, urbanization, and increasing female workforce participation have led to higher demand for effective birth control methods. Moreover, the availability of over-the-counter oral contraceptives in many regions has improved accessibility and affordability, driving market growth. Additionally, advancements in contraceptive research and development have led to the introduction of new formulations with improved efficacy, safety, and tolerability profiles, further fueling market expansion.

Region Insights:

The oral contraceptive pills market exhibits regional variations influenced by factors such as cultural norms, healthcare infrastructure, and regulatory frameworks. Developed regions such as North America and Europe dominate the market, driven by high awareness levels, favorable reimbursement policies, and widespread availability of contraceptive options. In contrast, emerging economies in Asia-Pacific and Latin America are witnessing rapid market growth due to increasing healthcare expenditure, expanding access to reproductive healthcare services, and government initiatives to address population growth.

Oral Contraceptive Pills Market Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 14.62%
Global Market Size in 2023USD 23.71 Billion
Global Market Size in 2024USD 27.18 Billion
Global Market Size by 2033USD 92.80 Billion
Largest MarketNorth America
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Type, By Category, and By Distribution Channel
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Oral Contraceptive Pills Market Dynamics

Drivers:

Several drivers propel the growth of the oral contraceptive pills market globally. Women’s empowerment and reproductive rights movements have led to increased autonomy in family planning decisions, driving demand for contraceptives. Moreover, the growing emphasis on women’s health and well-being, coupled with initiatives to improve access to reproductive healthcare services, has encouraged contraceptive use. Furthermore, public health campaigns and educational programs aimed at promoting contraceptive awareness and usage contribute to market growth by reducing social stigma and misconceptions surrounding contraception.

Opportunities:

The oral contraceptive pills market presents opportunities for innovation, product differentiation, and market expansion. Advancements in drug delivery technologies offer opportunities to develop novel formulations with improved safety, convenience, and patient adherence. Moreover, expanding into untapped markets such as rural areas and low-income communities presents opportunities for market growth by addressing unmet contraceptive needs. Furthermore, strategic collaborations between pharmaceutical companies, healthcare providers, and non-governmental organizations can help improve access to contraceptives and promote family planning initiatives globally.

Challenges:

Despite the growth opportunities, the oral contraceptive pills market faces several challenges. Concerns about the long-term safety and side effects of oral contraceptives, such as cardiovascular risks and hormonal imbalances, pose challenges to market acceptance and uptake. Additionally, cultural and religious beliefs, as well as legal restrictions, may limit contraceptive access and usage in certain regions. Moreover, supply chain disruptions, regulatory hurdles, and pricing pressures can impact market dynamics and hinder market growth. Addressing these challenges requires collaborative efforts from stakeholders across the healthcare ecosystem to ensure safe, effective, and affordable contraceptive options for women worldwide.

Read Also: Dental Cleaning Tablets Market Size, Share, Report by 2033

Oral Contraceptive Pills Market Recent Developments

  • In March 2024, the over-the-counter birth control drug Perrigo Opill has been dispatched to major retailers and pharmacies in the United States and will be available in shops and online later. Opill is scheduled to hit store shelves that focus on consumer self-care items.
  • In December 2023, a ground-breaking step toward shared responsibility in contraception, UK researchers launched the first stage of testing for a novel non-hormonal birth control tablet for men.
  • In April 2023, in an open letter signed on Monday, executives from over 300 biotech and pharmaceutical companies, including Pfizer and Biogen, called for the reversal of a federal judge’s order to halt the sale of the abortion drug mifepristone.

Oral Contraceptive Pills Market Companies

  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • AbbVie Inc.
  • Bayer AG
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Zydus Lifesciences Ltd
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Church & Dwight Co Inc.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Ferring B.V
  • Amneal Pharmaceuticals LLC
  • Lupin Pharmaceuticals Inc.
  • Vardhaman Lifecare Pvt. Ltd
  • Glenmark Pharmaceuticals
  • Piramal Enterprises Ltd.
  • Mankind Pharma Ltd.
  • Sopharma AD
  • Mayne Pharma
  • HLL Lifecare Limited
  • Famy Care Ltd
  • Syzygy Healthcare
  • V Care Pharma
  • Actavis PLC
  • Mylan N.V.

Segments Covered in the Report

By Type

  • Combination
    • Monophasic
    • Triphasic
    • Others
  • Progestin Only
  • Others

By Category

  • Generic
  • Branded

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online
  • Public Channel And NGO

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/